Soligenix to present on ThermoVax at vaccine conference

Soligenix, Inc., a clinical-stage biopharmaceutical company, announced on Tuesday that its Chief Scientific Officer Robert Brey will present at the 2014 World Vaccine Congress in Washington.

Brey will give a presentation entitled "Development of Thermostable Subunit Vaccines" at the event's Biotech Showcase. The presentation will take place at 2:10 p.m. on Tuesday, March 25 at the Marriott Wardman Park Hotel in Washington.

During the presentation, Brey will review Soligenix's achievements to date with its ThermoVax vaccine heat stabilization technology. ThermoVax is a technology meant to eliminate standard cold chain production, distribution and storage logistics required for most vaccines.

According to the Biopharma Cold Chain Sourcebook of 2010, 98 percent of all vaccines, with a value of $20.6 billion, require shipment through the cold chain. Eliminating the cold chain would increase the utility of these vaccines for applications that lack reliable cold chain capabilities. The World Health Organization estimates that 50 percent of all global vaccine doses are wasted because they are not kept within the required temperature ranges.

ThermoVax allows vaccines to withstand temperatures at least as high as 104 degrees Fahrenheit for up to one year.

The World Vaccine Conference seeks to provide customers with the relationships and big ideas they need to do different and better business. More than 500 global vaccine stakeholders attended last year's conference.

Soligenix focuses on developing products to treat serious inflammatory diseases and developing biodefense vaccines and therapeutics.